Vita Imaging is seeking an additional VA site for its study, “Raman Spectroscopy AURA for Non-Invasive Diagnosis of Skin Cancer: A Multi-Site Clinical Validation Study in the US.”
·Target Population: Men & women 18 years and older with lesions that meet inclusion criteria Fitzpatrick skin types I-VI with greater representation of skin types IV-V
·# of Sites: Total of 3 (Tampa and Boston are proposed sites)
·# of Subjects: Total of 300 (1 biopsy per subject)
Please note that the Tampa VA is already working with this sponsor, and has an approved CDA for this study (please contact Doug Reeder at the Tampa VA Research and Education Foundation for information about the CDA: [email protected]).
If you are interested in pursuing this study, please contact Victoria Reade at [email protected].
Regeneron Pharmaceuticals is seeking VA sites for its study, A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Patients with Early Stage Cutaneous Squamous Cell Carcinoma (CSCC).
If you are interested in pursuing this study, please contact Chris Isibor at [email protected].